Phase I pharmacokinetic profile and early clinical evaluation of the PAN-HER inhibitor BMS-599626

• DOI: 10.1200/jco.2005.23.16_suppl.3109
• Publication Date: 2017-02-23T18:55:09Z
• Authors: J. C. Soria; J. Cortes; J. P. Armand; A. Taleb; L. van Bree; E. Lopez; S. Song; K. Zeradib; F. Vazquez; R. E. Martell; J. Baselga
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

3109 Background: BMS-599626 is an orally bioavailable inhibitor of HER1 (EGFR), HER2 (ErbB2) and to a lesser extent HER4. Methods: This is a phase I dose escalation study of BMS-599626 administered...